# GSK invests $139M to expand biopharmaceutical plant in Rockville, Maryland

GSK announced a $139 million investment to expand its biopharmaceutical manufacturing site in Rockville, MD, to increase bulk drug substance production for BENLYSTA by close to 50%.

- Type: Expansion
- Announced: 2017-05-05
- Where: Rockville, MD, United States
- Value: $139.0M
- Status: announced
- Capacity: increase bulk drug substance production by close to 50%
- Products: BENLYSTA (belimumab)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [GSK](https://endata.com/companies/24071.md)

## Sources

- [us.gsk.com](https://us.gsk.com/en-us/media/press-releases/gsk-invests-139-million-to-expand-production-capacity-for-benlysta-belimumab-in-rockville-md/), 2017-05-05: "We are so pleased that on the first day of Lupus Awareness Month we are able to announce this expansion in Rockville, increasing our ability to provide this important medicine to patients."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.